Alnylam Pharmaceuticals
ALNY
#645
Rank
NZ$54.11 B
Marketcap
$419.52
Share price
-0.77%
Change (1 day)
55.76%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

P/S ratio for Alnylam Pharmaceuticals (ALNY)

P/S ratio as of November 2024 (TTM): 15.1

According to Alnylam Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 977. At the end of 2024 the company had a P/S ratio of 16.8.

P/S ratio history for Alnylam Pharmaceuticals from 2004 to 2024

PS ratio at the end of each year

Year P/S ratio Change
202416.828.24%
202313.1-53.38%
202228.217.32%
202124.0-21.59%
202030.6-47.89%
201958.8-40.29%
201898.5-29.73%
2017140105.69%
201668.1-65.05%
201519531.6%
201414870.45%
201386.9505.26%
201214.4241.19%
20114.210.83%
20104.17-43.09%
20097.33-31.15%
200810.7-54.28%
200723.3-20.88%
200629.4-34.68%
200545.133.85%
200433.7

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
117 673.81%๐Ÿ‡บ๐Ÿ‡ธ USA
5.92-60.76%๐Ÿ‡บ๐Ÿ‡ธ USA
7.24-52.06%๐Ÿ‡บ๐Ÿ‡ธ USA
1.50-90.08%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
4.19-72.27%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
2.28-84.91%๐Ÿ‡ซ๐Ÿ‡ท France
1.18-92.20%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel